Hauling in a $100M mega-round, gene therapy startup Generation Bio builds alternative to potentially risky viral vectors
A gene therapy company headed up by bigwigs and backed early on by Atlas has pulled in a mega-round of $100 million. The 2-year-old startup captured investors’ attention by suggesting it knows a better way to do gene transfer than the potentially toxic viral vector strategies of late.
Generation Bio is the Boston/Cambridge upstart, and it’s a company that’s strayed from the pack when it comes to the how of gene therapy. While its rivals in the field are buckling down on viral vehicles like adeno associated viruses (AAV), Generation Bio is taking a different route.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
